148 related articles for article (PubMed ID: 8952875)
1. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
Knoll J
Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
[No Abstract] [Full Text] [Related]
2. Treatment of Parkinson's disease.
Bergus G
J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
[No Abstract] [Full Text] [Related]
3. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
4. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
5. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
Olanow CW; Godbold JH; Koller W
BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
[No Abstract] [Full Text] [Related]
6. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
7. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
8. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
Papapetropoulos S; Argyriou AA
Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
[No Abstract] [Full Text] [Related]
9. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
10. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
11. Single vs multiple daily dosing of aminoglycosides.
Newton W
J Fam Pract; 1996 May; 42(5):456-7. PubMed ID: 8642359
[No Abstract] [Full Text] [Related]
12. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
13. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
Birkmayer W; Riederer P
Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111
[No Abstract] [Full Text] [Related]
14. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
16. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
18. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
19. L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Adv Neurol; 1990; 53():431-5. PubMed ID: 2122649
[No Abstract] [Full Text] [Related]
20. [Changing drug therapy of Parkinson disease].
Rinne UK
Duodecim; 1993; 109(20):1763-8. PubMed ID: 7736999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
